Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D006417:Hematuria / Q000139:chemically induced; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009846:Oliguria / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced
D003520:Cyclophosphamide; D007069:Ifosfamide